DNA Damage/DNA Repair
- MTH1(4)
- PARP(84)
- ATM/ATR(30)
- DNA Alkylating(20)
- DNA Ligases(3)
- DNA Methyltransferase(25)
- DNA-PK(30)
- HDAC(136)
- Nucleoside Antimetabolite/Analogue(140)
- Telomerase(17)
- Topoisomerase(151)
- tankyrase(5)
- Antifolate(38)
- CDK(250)
- Checkpoint Kinase (Chk)(31)
- CRISPR/Cas9(9)
- Deubiquitinase(72)
- DNA Alkylator/Crosslinker(71)
- DNA/RNA Synthesis(400)
- Eukaryotic Initiation Factor (eIF)(23)
- IRE1(23)
- LIM Kinase (LIMK)(9)
- TOPK(5)
- Casein Kinase(61)
- DNA Intercalating Agents(7)
- DNA/RNA Oxidative Damage(12)
Products for DNA Damage/DNA Repair
- Cat.No. Product Name Information
- GC32741 CCT-251921 CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM.
- GC18053 CCT241533 A selective Chk2 inhibitor
- GC17105 CCT241533 hydrochloride A selective Chk2 inhibitor
- GC14772 CCT244747 Potent and selective CHK1 inhibitor
- GC19093 CCT245737 CCT245737 is a orally active and seletive Chk1 inhibitor, with an IC50 of 1.3 nM.
- GC35628 Cdc7-IN-1 Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death.
- GC62427 Cdc7-IN-5 Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
- GC12425 CDK inhibitor II
- GC38899 CDK ligand for PROTAC hydrochloride
- GC62168 CDK-IN-6 CDK-IN-6, a class of pyrazolo[1,5-a]pyrimidine compound, is a CDK inhibitor with anticancer activities.
- GC63499 CDK12-IN-2 CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12.
- GC35632 CDK2-IN-4 CDK2-IN-4 is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM).
- GC65190 CDK4/6-IN-11 CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.
- GC35633 CDK4/6-IN-2 CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC50s of 2.7 and 16 nM for CDK4 and CDK6, respectively.
- GC35634 CDK4/6-IN-3 CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor with Kis of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a Ki of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma.
- GC64802 CDK4/6-IN-6 CDK4/6-IN-6 (example A94) is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively.
- GC60680 CDK5 inhibitor 20-223 CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC50s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent.
- GC66009 CDK5-IN-3 CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC50s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD).
- GC63980 CDK7-IN-2 CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1).
- GC62596 CDK7-IN-3 CDK7-IN-3 (CDK7-IN-3) is an orally active, highly selective, noncovalent CDK7 inhibitor with a KD of 0.065 nM. CDK7-IN-3 shows poor inhibition on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), CDK12 (Ki=870 nM). CDK7-IN-3 induces apoptosis in tumor cells and has antitumor activity.
- GC65434 CDK7/12-IN-1 CDK7/12-IN-1 is a selective CDK7/12 inhibitor with IC50s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth.
- GC60681 CDK7/9 tide CDK7/9 tide is peptide substrate for CDK7 or CDK9.
- GC33180 CDK8-IN-1 CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC50 of 3 nM.
- GC30466 CDK8-IN-3 CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7.
- GC33366 CDK8-IN-4 CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM.
- GC35635 CDK9 Antagonist-1
- GC12871 CDK9 inhibitor
- GC17359 CDK9 inhibitor 2
- GC66475 CDK9-IN-10 CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811).
- GC65262 CDK9-IN-13 CDK9-IN-13 (compound 38) is potent and selective CDK9 inhibitor, with an IC50 of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents.
- GC64446 CDK9-IN-15 CDK9-IN-15 (compound 50) is a potent CDK9 inhibitor.
- GC35636 CDK9-IN-7 CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC.
- GC65247 CDK9-IN-8 CDK9-IN-8 is a highly effective and selective CDK9 inhibitor with an IC50 of 12 nM.
- GC19096 CDKI-73 CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM; shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM).
- GC49307 cDPCP A DNA-crosslinking agent
- GC32181 Cefradine (Cephradine) Cefradine (Cephradine) (Cefradine) is a broad-spectrum and orally active cephalosporin.
- GC19098 CeMMEC1 CeMMEC1 is an inhibitor of BRD4, and also has high affinity for TAF1, with an IC50 of 0.9 uM for TAF1, and a Kd of 1.8 uM for TAF1 (2).
- GC19099 CeMMEC13 CeMMEC13 is a potent inhibitor of TAF1 (2) bromodomain, with an IC50 of 2.1 uM.
- GC64261 Censavudine Censavudine (OBP-601; BMS-986001), a nucleoside analog, is a nucleoside reverse transcriptase inhibitor.
- GC39484 Ceramides Mixture A mixture of ceramides
- GC35668 CG-200745 CG-200745 (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. CG-200745 inhibits deacetylation of histone H3 and tubulin. CG-200745 induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. CG-200745 enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine and 5-Fluorouracil (5-FU; ). CG-200745 induces apoptosis and has anti-tumour effects.
- GC14526 CGK733 ATM/ATR inhibitor,potent and selective
- GC60692 CH-0793076 TFA CH-0793076 (TP3076) TFA, a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 TFA inhibits DNA topoisomerase I with an IC50 of 2.3 μM. CH-0793076 TFA is efficacious against cells expressing BCRP (breast cancer resistance protein).
- GC18536 Chartreusin Chartreusin is an antibiotic originally isolated from S.
- GC64942 CHDI-390576 CHDI-390576, a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor with IC50s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.
- GC32250 Chebulinic acid An ellagitannin with diverse biological activities
- GC16042 Chidamide Chidamide (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.
- GC15739 CHIR-124 Chk1 inhibitor,novel and potent
- GC33392 CHK-IN-1 CHK-IN-1 is an inhibitor of CHK1 and CHK2, with anti-proliferative activities.
- GC30106 CHK1 inhibitor CHK1 inhibitor (GDC-0575 analog) is an inhibitor of CHK1.
- GC33289 CHK1-IN-2 CHK1-IN-2 is a checkpoint kinase 1 (CHK1) inhibitor, with an IC50 of 6 nM.
- GC35679 CHK1-IN-3 CHK1-IN-3 is a Checkpoint Kinase 1 (CHK1) inhibitor with an IC50 of 0.4 nM.
- GC60698 Chk1-IN-5 Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model.
-
GC12908
Chlorambucil
nitrogen mustard alkylating agent
- GC60107 Chloroquinoxaline sulfonamide Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison.
- GC35693 CI 972 (anhydrous) CI 972 (anhydrous) is a potent, orally active, and competitive inhibitor of purine nucleoside phosphorylase (PNP) (Ki=0.83 μM) under development as a T cell-selective immunosuppressive agent.
- GC65878 Cimpuciclib tosylate Cimpuciclib tosylate is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity.
- GC63476 Cirtuvivint Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research.
- GC18640 cis-9,10-Methyleneoctadecanoic Acid methyl ester cis-9,10-Methyleneoctadecanoic acid methyl ester is a cyclopropane fatty acid methyl ester.
- GC11908 Cisplatin Cisplatin is one of the best and first metal-based chemotherapeutic drugs, which is used for wide range of solid cancers such as testicular, ovarian, bladder, lung, cervical, head and neck cancer, gastric cancer and some other cancers.
- GC52351 Citrullinated α-Enolase (R8 + R14) (1-19)-biotin Peptide A biotinylated and citrullinated α-enolase peptide
- GC34536 CK1-IN-1 CK1-IN-1 is a casein kinase 1 (CK1) inhibitor extracted from patent WO2015119579A1, compound 1c, has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.
- GC62337 CK2 inhibitor 2 CK2 inhibitor 2 is a potent, selective and orally active inhibitor of CK2, with an IC50 of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC50=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity.
- GC39485 CK2/ERK8-IN-1 A dual inhibitor of CK2 and ERK8
- GC63800 CK7 CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
- GC50105 CKD 602 Topoisomerase I inhibitor
- GC38755 CKI-7 CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases.
- GC47098 CL2-SN-38 (dichloroacetic acid salt) An antibody-drug conjugate containing SN-38
- GC60714 CL2A-SN-38 An antibody-drug conjugate containing SN-38
- GC10509 Cladribine Apoptosis inducer in CLL cells
- GC49852 Clindamycin (hydrochloride hydrate) Clindamycin (hydrochloride hydrate) is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs).
- GC52171 Clindamycin-d3 (hydrochloride) Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin.
- GC30245 CLK1-IN-1 CLK1-IN-1 is a potent and selective of Cdc2-like kinase 1 (CLK1) inhibitor, with an IC50 of 2 nM.
- GC15219 Clofarabine Antimetabolite,inhibit DNA polymerase and ribonucleotide reductase
- GC33320 CM-579 CM-579 is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.
- GC35714 CM-579 trihydrochloride CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells.
- GC65426 CM-675 CM-675 is a dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC50 values of 114 nM and 673 nM for PDE5 and HDAC1, respectively.
- GC62698 CMLD012612 CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity.
- GC33327 CMPD 7 CMPD 7 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay.
- GC33177 CNDAC CNDAC is a major metabolite of oral drug sapacitabine, and a nucleoside analog.
- GC38382 CNDAC hydrochloride CNDAC hydrochloride is a metabolite of the orally active agent sapacitabine, and a nucleoside analog.
- GC19110 COH29 COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity.
- GC10812 Compound 401 DNA-PK and mTOR inhibitor
- GC61965 Coralyne chloride Coralyne chloride is a protoberberine alkaloid with potent anti-cancer activities. Coralyne chloride acts as a potent topoisomerase I poison and induces Top I mediated DNA cleavage. Coralyne chloride can be used for preparing?coralyne derivatives?as DNA binding fluorescent probes.
- GC34165 Corin Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a Ki(inact) of 110 nM for LSD1 and an IC50 of 147 nM for HDAC1.
- GC16116 Costunolide A natural sesquiterpene lactone
- GC35739 CP-10 CP-10 is a PROTAC connected by ligands for Cereblon and CDK, with highly selective, specific, and remarkable CDK6 degradation (DC50=2.1 nM). It inhibits proliferation of several haematopoietic cancer cells with impressive potency including multiple myeloma, and can still degrades mutated and overexpressed CDK6.
- GC16489 CP-466722 ATM inhibitor,potent and reversible
- GC68455 CP681301
- GC32565 CRA-026440 CRA-026440 is a potent, broad-spectrum HDAC inhibitor.
- GC67674 CRA-026440 hydrochloride
- GC38412 Crotonoside A guanosine analog with diverse biological activities
- GC50404 CRT 0105950 Potent LIMK1/2 inhibitor
- GC17231 CRT0044876 APE1 inhibitor, potent and selective
- GC65023 CTX-712 CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286).
- GN10526 Cucurbitacin E
- GC18028 CVT-313 A Cdk2 inhibitor
- GC13037 CX-4945 (Silmitasertib) CX-4945 (Silmitasertib) (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
- GC11325 CX-4945 sodium salt CX-4945 sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
- GC14404 CX-5461 Pol I-mediated rRNA synthesis inhibitor